|
137
|
339
|
6zqzA |
[1,2,4]triazolo[1,5-a]pyrimidine phosphodiesterase 2 inhibitors |
|
123
|
312
|
7bpiA |
The crystal structue of pde10a complexed with 14 |
|
127
|
326
|
6zndA |
[1,2,4]triazolo[1,5-a]pyrimidine phosphodiesterase 2 inhibitors |
|
142
|
354
|
6blfA |
Pde2 complexed with 2-[6-fluoro-8-methylsulfonyl-9-[(1r)-1-[4-(trifluoromethyl)phenyl]ethyl]-1,2,3,4-tetrahydrocarbazol-1-yl]acetic acid |
|
130
|
328
|
6msaA |
Novel, potent, selective and brain penetrant phosphodiesterase 10a inhibitors |
|
134
|
322
|
6mscA |
Novel, potent, selective and brain penetrant phosphodiesterase 10a inhibitors |
|
120
|
323
|
5znlA |
Crystal structure of pde10a catalytic domain complexed with lhb-6 |
|
113
|
324
|
6ijiA |
Crystal structure of pde10 in complex with inhibitor 2b |
|
122
|
322
|
6ijhA |
Crystal structure of pde10 in complex with inhibitor af-399/14387019 |
|
115
|
312
|
5k9rA |
Pde10a with imidazopyrazine inhibitor |
|
130
|
313
|
5i2rA |
Human pde10a in complex with 3-(2-phenylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one |
|
140
|
342
|
6ezfA |
Pde2 in complex with molecule 5 |
|
135
|
352
|
6cycA |
Pde2 in complex with compound 5 |
|
132
|
352
|
6cydA |
Pde2 in complex with compound 7 |
|
134
|
352
|
6cybA |
Pde2 in complex with compound 7 |
|
135
|
342
|
6c7dA |
Crystal structure of human phosphodiesterase 2a with n-(1-adamantyl)-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
137
|
342
|
6c7eA |
Crystal structure of human phosphodiesterase 2a with 1-(2-chlorophenyl)-n,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
140
|
339
|
6c7fA |
Crystal structure of human phosphodiesterase 2a with 1-(2-chloro-5-isobutoxy-phenyl)-n,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
136
|
342
|
6c7jA |
Crystal structure of human phosphodiesterase 2a with 1-(5-tert-butoxy-2-chloro-phenyl)-n-isobutyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
136
|
342
|
6c7iA |
Crystal structure of human phosphodiesterase 2a with 1-(2-chloro-5-methoxy-phenyl)-n-isobutyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
133
|
341
|
6c7gA |
Crystal structure of human phosphodiesterase 2a with n-(1-adamantyl)-1-(2-chloro-5-isobutoxy-phenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
134
|
352
|
6b97A |
Crystal structure of pde2 in complex with complex 9 |
|
130
|
353
|
6b98A |
Pde2 in complex with compound 1 |
|
136
|
352
|
6b96A |
Crystal structure of pde2 in complex with compound 16 |
|
132
|
340
|
5xkmA |
Crystal structure of human phosphodiesterase 2a in complex with 6-methyl-n-(1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide |
|
125
|
322
|
5xuiA |
Crystal structure of pde10a in complex with 2-methyl-5-[2-([1,2,4]triazolo[1,5-a]pyrimidin-2-yl)et hyl]pyrazolo[1,5-a]pyrimidin-7-ol |
|
121
|
322
|
5xujA |
Crystal structure of pde10a in complex with 7-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]pyrimidine |
|
135
|
353
|
5w6eA |
Pde1b complexed with compound 3s |
|
130
|
338
|
5u7iA |
Pde2 catalytic domain complexed with inhibitors |
|
126
|
307
|
5c29A |
Pde10 complexed with 6-chloro-2-cyclopropyl-5-methyl-n-propyl-pyrimidin-4-amine |
|
127
|
323
|
5c2eA |
Pde10 complexed with6-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[2-(2-pyridyl)ethoxy]pyrimidin-4-amine |
|
136
|
325
|
5c28A |
Pde10 complexed with 6-chloro-2-cyclopropyl-5-methyl-pyrimidin-4-amine |
|
126
|
308
|
5c2hA |
Pde10 complexed with 6-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[3-(2-quinolyl)propoxy]pyrimidin-4-amine |
|
135
|
325
|
5c1wA |
Pde10 complexed with 4,6-dichloro-2-cyclopropyl-5-methyl-pyrimidine |
|
133
|
323
|
5c2aA |
Pde10 complexed with 6-chloro-2-cyclopropyl-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-pyrimidin-4-amine |
|
147
|
335
|
5b25A |
Crystal structure of human pde1b with inhibitor 3 |
|
125
|
315
|
5b4lA |
Crystal structure of the catalytic domain of human pde10a complexed with 1-(cyclopropylmethyl)-5-(2-(2,3-dihydro-1h-imidazo[1,2-a]benzimidazol-1-yl)ethoxy)-3-(1-phenyl-1h-pyrazol-5-yl)pyridazin-4(1h)-one |
|
126
|
322
|
4ys7A |
Co-crystal structure of 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-3-methyl-3h-imidazo[4,5-f]quinoline (compound 39) with pde10a |
|
128
|
321
|
4yqhA |
2-[2-(4-phenyl-1h-imidazol-2-yl)ethyl]quinoxaline (sunovion compound 14) co-crystallized with pde10a |
|
137
|
338
|
4htzA |
Crystal structure of pde2 catalytic domain in space group p1 |
|
135
|
338
|
4htxA |
Crystal structure of pde2 catalytic domain in complex with bay60-7550 |
|
128
|
318
|
4ddlA |
Pde10a crystal structure complexed with novel inhibitor |
|
124
|
307
|
4dffA |
The sar development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10a inhibitors for the treatment of schizophrenia |
|
131
|
340
|
4d09A |
Pde2a catalytic domain in complex with a brain penetrant inhibitor |
|
136
|
339
|
4d08A |
Pde2a catalytic domain in complex with a brain penetrant inhibitor |
|
128
|
325
|
4c1iA |
Selective inhibitors of pde2, pde9, and pde10: modulators of activity of the central nervous system |
|
124
|
312
|
4bbxA |
Discovery of a potent, selective and orally active pde10a inhibitor for the treatment of schizophrenia |
|
140
|
328
|
4ajfA |
Identification and structural characterization of pde10 fragment inhibitors |
|
131
|
320
|
4aelA |
Pde10a in complex with the inhibitor az5 |
|
133
|
324
|
4ajdA |
Identification and structural characterization of pde10 fragment inhibitors |
